Zoetis Inc dividend yield calculator – Zoetis is an Excellent Dividend Growth Stock, Says Seeking Alpha’s Leo Nelissen
January 31, 2023
Trending News ☀️
Zoetis Inc dividend yield calculator – Zoetis Inc ($NYSE:ZTS). (NYSE: ZTS) is an excellent dividend growth stock according to Leo Nelissen from Seeking Alpha in his article. Zoetis is a global animal health company that develops, manufactures, and commercializes a range of animal health products, including vaccines, pharmaceuticals, and other medical products. The company operates in the United States, Europe, and other regions. Zoetis has a strong portfolio of products and services, which includes vaccines, pharmaceuticals, diagnostics, veterinary biologicals, and other animal-health products. The company is also a leader in biologics, with a portfolio of products including vaccines, diagnostics, and other biologics.
In addition, Zoetis provides veterinary services such as pet health insurance and veterinary practice management software. Since then, Zoetis has increased its dividend payments each year. When evaluating Zoetis as a dividend growth stock, investors should consider the company’s strong financials. The company has a strong portfolio of products, a strong balance sheet, and a low payout ratio. Investors looking for a dividend growth stock should consider Zoetis as a potential option.
Dividends – Zoetis Inc dividend yield calculator
The company has been steadily increasing its dividend payments over the last three years. The dividend yields from 2020 to 2022 are 0.62%, 0.58%, and 0.57%, with an average dividend yield of 0.59%. The company’s consistent dividend growth is a sign of its financial strength, indicating that it is well-positioned to continue to reward shareholders with dividend payments in the future.
Additionally, the company’s low payout ratio ensures its ability to continue to pay dividends even during a downturn in the economy. Its consistent dividend growth and low payout ratio provide investors with the assurance that their investment will be rewarded in the form of steady dividend payments for years to come.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zoetis Inc. More…
| Total Revenues | Net Income | Net Margin |
| 8.01k | 2.07k | 26.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zoetis Inc. More…
| Operations | Investing | Financing |
| 1.85k | -587 | -2k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 13.67k | 9.01k | 10 |
Key Ratios Snapshot
Some of the financial key ratios for Zoetis Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.2% | 13.2% | 34.8% |
| FCF Margin | ROE | ROA |
| 15.8% | 37.6% | 12.7% |
Share Price
The article noted that news coverage surrounding the company has been mostly positive and that it has a history of consistent dividend payments. On Tuesday, ZOETIS INC stock opened at $160.7 and closed at $159.6, down by 0.8% from prior closing price of 160.9. ZOETIS INC is a leading global animal health company, providing medicine and vaccinations for livestock and pets. Their portfolio includes products for companion animals, such as flea and tick prevention and treatments, as well as livestock vaccines. The company has a strong focus on innovation, and a diverse product portfolio for animals of all kinds.
The company has a long history of providing consistent dividends to its shareholders. This demonstrates the company’s commitment to rewarding its shareholders. The company’s commitment to innovation and dividend payments makes it a reliable and attractive investment. Although the stock may have experienced some losses on Tuesday, long-term investors will benefit from this strong dividend paying stock. Live Quote…
VI Analysis
ZOETIS INC is a company that has been assessed for its long-term potential through its fundamentals by the VI app. The VI Star Chart shows that the company has achieved a high health score of 9/10, which is indicative of its ability to sustain its operations even during times of economic crisis. It has been rated highly in terms of dividend, growth, and profitability, while its asset ratings are only medium. Furthermore, it is classified as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Investors interested in such companies typically look for stability and low risk in their investments. Since ZOETIS INC has a high health score and is rated highly in dividend, growth, and profitability, it is an attractive investment opportunity for such investors. Moreover, the moderate revenue and earnings growth mean that the company is likely to have some potential for further growth, which could make it even more attractive to investors. Thus, investors looking for stable and low-risk investments with some potential for future growth may find ZOETIS INC to be an attractive option. More…
VI Peers
Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.
– BioGaia AB ($OTCPK:BIOGY)
Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
– Krka d.d. ($LTS:0HLK)
Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.
Summary
Zoetis Inc. is a leading animal health company that specializes in the development, manufacture, and commercialization of pharmaceuticals, vaccines, and other health products for pets, livestock, and other animals. According to Seeking Alpha’s Leo Nelissen, Zoetis is an excellent dividend growth stock with a strong track record of increasing its dividend each year. News coverage of the company has been largely positive, indicating that it is a good choice for investors looking for long-term growth potential.
Zoetis offers a diverse portfolio of products and services, including diagnostics, vaccines, anti-infectives, parasiticides, and other pharmaceuticals. With its strong financials and experienced management team, Zoetis is well positioned to continue to grow and provide excellent returns for investors.
Related Posts
Recent Posts
